The News Review:
- Get the New Directory of Clinical Research Companies in India.
- Doctors `Repeatedly or Deliberately’ Break FDA Drug-Trial Rules
- CRI Worldwide Appoints Peter H. Glick and Gwen H. Booth to Board of…
- Gift Establishes Ronald . Perelman Heart Institute: A ‘Medical…
- Q4 2007 EPICEPT CRP Earnings Conference Call – Final.
Get the New Directory of Clinical Research Companies in India.
Free with registration – Business Wire – AccessMyLibrary.com – Feb 29, 2008
researchandmarkets. India is fast emerging as a favoured destination for clinical trials by global pharmaceutical and biotech companies that are looking for partnerships or setting up new operations. Two major reasons for its popularity are: easy access and availability of a large diverse and therapy-naive population with vast gene pool and lower cost of technical services resulting into lower per patient trial cost.
Doctors `Repeatedly or Deliberately’ Break FDA Drug-Trial Rules
Bloomberg – Feb 29, 2008
`The Worst Mess' “Every study that I got my hands onto — it was the worstmess'' Pelletier said of her review of studies Lawton handled. “I've been a researcher for 12 years and I've never seenanything like this. '' Pelletier now works as a clinical research coordinator foranother firm. Vestal responded to the FDA investigators' findings with aletter promising changes in procedures in future drug trials. The investigators sent their report to headquarters insuburban Washington. More than three years passed. Former agency employees who oversaw clinical researchincluding Stan Woollen said long delays are typical because toofew people are doing too much work… The investigators sent their report to headquarters insuburban Washington. More than three years passed. Former agency employees who oversaw clinical researchincluding Stan Woollen said long delays are typical because toofew people are doing too much work. The process for discipliningresearchers is also too bureaucratic said Woollen who wasn'tinvolved in the Vestal case. `Dysfunctional' Process “The disqualification process has been dysfunctional inthe FDA for years'' said Woollen who retired from the agencyin 2006 and worked in a division that regulated clinical trials. With the FDA taking no action against him Vestal was freeto do more trials. He went on to test experimental prostatecancer treatments made by Myriad Genetics Inc.
CRI Worldwide Appoints Peter H. Glick and Gwen H. Booth to Board of…
Free with registration – Business Wire – AccessMyLibrary.com – Feb 29, 2008
– CRI Worldwide Inc. a leading provider of clinical research services to the global pharmaceutical and biotech industry has elected Peter H. Glick General Partner Ampersand Ve.
Gift Establishes Ronald . Perelman Heart Institute: A ‘Medical…
Medical News Today – Medical News Today (press release) – Feb 29, 2008
The Institute will expand upon the Hospital’s cardiac care expertise and connect all cardiac services from treating life-threatening arrhythmias to complex coronary artery disease. The generous support from Mr. Perelman will also make possible the recruitment of additional top-ranked physician-scientists and the promotion of translational and clinical research efforts aimed at new ways to diagnose and treat patients with heart disease. New interventional cardiology labs will be equipped with the latest technology and allow physicians to continue to develop advances in minimally invasive procedures that ensure quicker recovery and shorter hospital stays for patients. “Quality care is truly a team effort. Perelman Heart Institute patients and their families will be treated like honored guests.
Q4 2007 EPICEPT CRP Earnings Conference Call – Final.
Free with registration – Fair Disclosure Wire – AccessMyLibrary.com – Feb 29, 2008
Such forward-looking statements include statements which express plans anticipation intent contingency goals targets future development and are otherwise not statements of historical fact. These statements are based on EpiCept’s current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.
